ExeVir Bio | Valuation, Funding Rounds & Stock Price | Caplight
ExeVir Bio
Private
Belgium
Healthcare & Life Sciences ExeVir Website
Last Round: Grant
Date: Jun 28, 2023
Total Funding Raised: $108.78M
Company Overview
ExeVir Bio is a biotechnology company that develops single-domain antibody-based therapies for the treatment and prevention of infectious diseases.
Sector: Healthcare & Life Sciences
Verticals: Biotechnology, Drug Discovery, Clinical Trials
Business Model: B2B
Customer Profile: Services & Consulting
AI Layer: Non-AI
Keywords: nanobody, vhh, antibody, antibody therapy, camelid antibody, biotech, drug discovery, monoclonal antibody, viral infection treatment, clinical-stage biotech, multispecific antibody, cdmo partnership, drug pipeline, llama-derived antibody
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Unlock Pricing Charts
Sign up to view complete historical pricing and secondary transactions.
Caplight Momentum Score
Proprietary index based on bid/ask volume and sentiment.
View Momentum History
Track how buyer interest and sentiment changes over time.
ExeVir Bio Comparables
Compare ExeVir Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiosCURE Therapeutics SE | 89% | Unlock |
| Cerberus Therapeutics | 82% | Unlock |
| Invivyd | 79% | Unlock |
| Comparable company | 50% | Unlock |
ExeVir Bio Funding Rounds
Historical fundraising activity.
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 28, 2023 | Unlock | Unlock | Unlock | Unlock |
| Debt | Dec 14, 2022 | Unlock | Unlock | Unlock | Unlock |
| Grant | Jul 13, 2021 | Unlock | Unlock | Unlock | Unlock |
| Series A | Mar 16, 2021 | Unlock | Unlock | Unlock | Unlock |
| Series A | Jul 28, 2020 | Unlock | Unlock | Unlock | Unlock |
Key People
Founding team and executive leadership
Michael Garrett
Chief Executive Officer
LinkedIn profileCaroline Sagaert
COO
LinkedIn profile
ExeVir Bio Investors
Notable investors and investment history.
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| Federal Holding and Investment Company | Series A |
| Sopartec | Series A |
| Noshaq | Series A |
| Fund+ | Series A |
| Société Régionale d'Investissement de Wallonie | Series A |
| UCB Ventures | Series A |
Market Signals
- Jun 28, 2023: $1.74M grant received from VLAIO.
- Dec 14, 2022: $27M round from European Investment Bank Group.
ExeVir Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
- Is ExeVir Bio a public or private company?
- What is the current stock price of ExeVir Bio?
- How much is ExeVir Bio worth (valuation)?
- Can I buy ExeVir Bio stock?
- When was ExeVir Bio's last funding round?
- Who are the main investors in ExeVir Bio?
- Will ExeVir Bio IPO soon?
- How can I track ExeVir Bio secondary market activity?
Firmographic Details
- Headquarters: Belgium
- Employee Range: 10
- Year Founded: 2020
- Last Funding: Jun 28, 2023